Amarin Says REDUCE-IT Post Hoc Analysis Showed About 30% Relative Risk Reduction In Major Adverse Cardiovascular Events Among Patients On Icosapent Ethyl At Least 1.5 Years; Hazard Ratio Of 0.73 Persisted After Discontinuation
Share
Why It Matters
Amarin looked back at patient data and found their heart medicine might help people avoid serious heart problems by about 30%. This suggests the medicine's benefits may stick around even after people stop taking it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.